Tag: health

- XIPERE Now Approved for Use in Multiple Global Markets -

MISSISSAUGA, Ontario, July 23, 2025 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), is pleased to announce that it is entering into a loan agreement with certain existing directors and officers of the Company (the “Lenders”) providing for the advance of an unsecured loan (the “Loan”) bearing interest at 5.0% per annum in the principal amount of $530,000. The Loan shall mature on the date that is one year from the advance of the Loan (the “Maturity Date”).   In conjunction with the advance of the Loan, the Company will also pay a set-up fee of $20,000 to the Lenders.

Rogers delivers strong results and completion of transformational investments in the second quarter

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Inferior Vena Cava IVC Filter Market size & share revenue was valued at approximately USD 895.82 Million in 2024 and is expected to reach USD 974.16 Million in 2025 and is expected to reach around USD 2,094.10 Million by 2034, at a CAGR of 8.88% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Canon Medical Systems, Cardinal Health, Cook, Esaote SpA, General Electric Company, Hologic, Inc., Koninklijke Philips N.V., Samsung Healthcare, Shimadzu Corporation, Siemens Healthcare Private Limited, Stryker, Terumo Europe NV and others.

Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has approved "getacatetide" as the International Nonproprietary Name (INN) of CY-101.

NEW YORK CITY and NEW ORLEANS, July 22, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.